Core Viewpoint - Digi Power X Inc. has successfully entered into a securities purchase agreement for the sale of 4,807,693 shares at an offering price of U.S.$3.12 per share, resulting in gross proceeds of approximately U.S.$15 million, which will enhance its financial position and support its growth strategy in AI and digital infrastructure [2][3][9]. Financial Highlights - The offering is expected to close on or about July 22, 2025, subject to regulatory approval [4]. - Post-offering, the company will have over U.S.$30 million in cash and cash equivalents, with no long-term debt [3][9]. - The financing is aimed at solidifying the company's capital position as it transitions from deployment to monetization [4]. Strategic Initiatives - The funds will be utilized to expand the deployment of NeoCloud Tier 3 AI infrastructure powered by NVIDIA B200 and B300 chips [9]. - The company plans to accelerate the manufacturing and global distribution of its ARMS 200 pods [9]. - The financing will support strategic joint ventures and PPA-backed energy deployments, as well as non-dilutive financing initiatives [9]. Market Position - The offering reflects a growing interest in the company's scalable AI infrastructure strategy, particularly its proprietary ARMS 200 Tier 3 modular data center platform and NeoCloud GPU-as-a-Service infrastructure [3][9]. - Titan Partners Group is acting as the sole placement agent for this offering [4].

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share (“iTeos Common Stock”), plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of iTeos in exc ...

HIGHLIGHTS US$450 million project loan facility secured from new strategic partner Appian Capital Advisory to fund the development and construction of the Cariboo Gold Project in B.C., Canada US$100 million initial draw enables the Company to accelerate project pre-construction activities and materially de-risk the ProjectUS$350 million in subsequent draws available on a final investment decision subject to certain customary project milestones and conditions precedent Strong endorsement and cornerstone fina ...

Shenzhen, China, July 21, 2025 (GLOBE NEWSWIRE) -- The DL7400 Series Office Adapter Family Welcomes a New Addition WAVLINK, launched its landmark new series of docking stations, built on the industry-leading DisplayLink® Pro DL-7400 . Engineered for data-driven professionals, software engineers, and modern enterprises, this series is designed to deliver an unprecedented multi-display desktop experience, powering up to five monitors from a single USB-C cable and supporting resolutions up to 8K@60Hz. The WAV ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populationsReflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a signific ...

PETAH TIKVA, Israel, July 21, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that it will release its second quarter 2025 financial results on Wednesday, August 6th, 2025. Conference Call and Webcast Following the release, Adi Sfadia, Chief Executive Officer, and Gil Benyamini, Chief Financial Officer, will discuss Gilat’s second quarter 2025 results and business achievements an ...

Second Quarter Highlights Net income of $19.2 million, or $0.61 per diluted share; return on average assets (“ROAA”) of 1.53%; return on average stockholders' equity (“ROAE”) of 13.47%; and return on average tangible common equity (“ROATCE”)(1) of 15.55%Adjusted net income(1) of $19.8 million; or $0.63 per diluted share; adjusted ROAA(1) of 1.58%; adjusted ROAE(1) of 13.87%; and adjusted ROATCE(1) of 16.02%Asset quality remained strong with nonperforming assets to total assets of 0.13% and net charge-offs t ...

Newly Deployed Strains Deliver Strong Performance in Initial Field Rearing Cycles, Paving the Way for Accelerated Deployment of Next-Generation TransgenicsANN ARBOR, Mich., July 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces the successful completion of the first rearing cycles for its three newest recombinant spider silk production strains. These newly developed strains were transitioned from the ...

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webc ...

CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating condition with no new FDA-approved treatments in over 15 years. “Millions of individuals impacted by fibromyalgia have suffered in silence for far too long,” said Thomas ...